CN1269482C - 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 - Google Patents
钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 Download PDFInfo
- Publication number
- CN1269482C CN1269482C CNB011180986A CN01118098A CN1269482C CN 1269482 C CN1269482 C CN 1269482C CN B011180986 A CNB011180986 A CN B011180986A CN 01118098 A CN01118098 A CN 01118098A CN 1269482 C CN1269482 C CN 1269482C
- Authority
- CN
- China
- Prior art keywords
- morphine
- ion channel
- channel blocker
- application
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 108010052164 Sodium Channels Proteins 0.000 title claims abstract description 20
- 102000018674 Sodium Channels Human genes 0.000 title claims abstract description 20
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 13
- 239000000014 opioid analgesic Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 241000124008 Mammalia Species 0.000 title claims description 4
- 230000036592 analgesia Effects 0.000 title abstract description 8
- 229940079593 drug Drugs 0.000 title description 15
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims abstract description 129
- 229960005181 morphine Drugs 0.000 claims abstract description 64
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 claims description 33
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 claims description 32
- 229950010357 tetrodotoxin Drugs 0.000 claims description 32
- 108091006146 Channels Proteins 0.000 claims description 7
- 229910001415 sodium ion Inorganic materials 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 claims description 4
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 claims description 4
- -1 methoxyl group Chemical group 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 241000054452 Takifugu ocellatus Species 0.000 claims 7
- 239000003053 toxin Substances 0.000 claims 7
- 231100000765 toxin Toxicity 0.000 claims 7
- MWPMJZZQPDXVJT-UHFFFAOYSA-N Tetrodonic acid Natural products N1C(N)=NC2OC(C(O)=O)C31C2C(O)C(O)(CO)C(O)C3O MWPMJZZQPDXVJT-UHFFFAOYSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 230000000146 antalgic effect Effects 0.000 claims 1
- MWPMJZZQPDXVJT-JTUKEBEQSA-N tetrodonicacid Chemical compound [C@]12([C@H](C(O)=O)O[C@@H]3N=C(N1)N)[C@@H]3[C@@H](O)[C@@](O)(CO)[C@H](O)[C@@H]2O MWPMJZZQPDXVJT-JTUKEBEQSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 33
- 208000002193 Pain Diseases 0.000 description 25
- 230000036407 pain Effects 0.000 description 23
- 241000700159 Rattus Species 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 12
- 229960005195 morphine hydrochloride Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 5
- 238000002690 local anesthesia Methods 0.000 description 5
- 230000001473 noxious effect Effects 0.000 description 5
- 210000003594 spinal ganglia Anatomy 0.000 description 5
- 210000000548 hind-foot Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- STNXQECXKDMLJK-UHFFFAOYSA-N (4betaO)-4,9-anhydro-tetrodotoxin Natural products C12C(C3(O)CO)OC4(O)C5OC2N=C(N)NC15C(O)C3O4 STNXQECXKDMLJK-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- STNXQECXKDMLJK-NLWUVLGBSA-N anhydroepitetrodotoxin Chemical compound C12C([C@@]3(O)CO)O[C@@]4(O)[C@H]5OC2N=C(N)N[C@@]15[C@H](O)[C@@H]3O4 STNXQECXKDMLJK-NLWUVLGBSA-N 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- COVOMQKTVSVWBZ-CJCGOCGYSA-N deoxytetrodotoxin Chemical compound O1C(C2(O)CO)(O)OC3C(O)C1[C@@H]1CN=C(N)NC12C3O COVOMQKTVSVWBZ-CJCGOCGYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- CUHVTYCUTYWQOR-UHFFFAOYSA-N formaldehyde Chemical compound O=C.O=C CUHVTYCUTYWQOR-UHFFFAOYSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011180986A CN1269482C (zh) | 2001-05-18 | 2001-05-18 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
| US10/062,483 US6780866B2 (en) | 2001-05-18 | 2002-02-05 | Analgesic composition and method |
| CA002485337A CA2485337C (en) | 2001-05-18 | 2002-05-20 | Analgesic composition and method |
| PCT/CN2002/000339 WO2002094272A1 (en) | 2001-05-18 | 2002-05-20 | Analgesic composition and method |
| DE60236077T DE60236077D1 (de) | 2001-05-18 | 2002-05-20 | Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker |
| JP2002590989A JP2004529959A (ja) | 2001-05-18 | 2002-05-20 | 鎮痛剤組成物と手法 |
| ES02734980T ES2344631T3 (es) | 2001-05-18 | 2002-05-20 | Composicion analgesica que comprende un opiaceo y un bloqueante de los canales del sodio. |
| AT02734980T ATE464903T1 (de) | 2001-05-18 | 2002-05-20 | Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker |
| EP02734980A EP1387685B1 (en) | 2001-05-18 | 2002-05-20 | Analgesic composition comprising an opioid and a sodium channel blocker |
| US10/849,240 US20040214842A1 (en) | 2001-05-18 | 2004-05-20 | Analgesic composition and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011180986A CN1269482C (zh) | 2001-05-18 | 2001-05-18 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1386505A CN1386505A (zh) | 2002-12-25 |
| CN1269482C true CN1269482C (zh) | 2006-08-16 |
Family
ID=4662967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011180986A Expired - Fee Related CN1269482C (zh) | 2001-05-18 | 2001-05-18 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6780866B2 (https=) |
| EP (1) | EP1387685B1 (https=) |
| JP (1) | JP2004529959A (https=) |
| CN (1) | CN1269482C (https=) |
| AT (1) | ATE464903T1 (https=) |
| CA (1) | CA2485337C (https=) |
| DE (1) | DE60236077D1 (https=) |
| ES (1) | ES2344631T3 (https=) |
| WO (1) | WO2002094272A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284536C (zh) * | 2000-09-18 | 2006-11-15 | 威克斯医药有限公司 | 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用 |
| CN1269482C (zh) * | 2001-05-18 | 2006-08-16 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
| MXPA04004543A (es) | 2001-11-15 | 2005-03-31 | Micro Algae Corp | Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal. |
| CN1568999A (zh) | 2003-07-14 | 2005-01-26 | 南宁枫叶药业有限公司 | 稳定的医药用河豚毒素冷冻干燥制剂 |
| JP2007538010A (ja) * | 2004-05-07 | 2007-12-27 | ファイトトックス リミテッド | フィコトキシンの経皮投与 |
| JP2007536269A (ja) * | 2004-05-07 | 2007-12-13 | ファイトトックス リミテッド | ゴニオトキシンを用いた創傷の治療方法 |
| CN101039675A (zh) * | 2004-09-22 | 2007-09-19 | 埃斯蒂文博士实验室股份有限公司 | 河豚毒素及其衍生物用于治疗外周神经源性神经痛 |
| EP1702627A1 (en) * | 2005-03-18 | 2006-09-20 | Laboratorios Del Dr. Esteve, S.A. | Analgesic combination of sodium channel blockers with opioid antagonists |
| US20100048592A1 (en) * | 2005-08-25 | 2010-02-25 | Wex Pharmaceuticals Inc. | Use of sodium channel blockers for the management of musculoskeletal pain |
| WO2007025212A2 (en) * | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| ES2691411T3 (es) | 2006-03-27 | 2018-11-27 | Wex Medical Limited | Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022899A (en) | 1973-06-12 | 1977-05-10 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
| US4906779A (en) * | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| US5262568A (en) * | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
| WO1993013128A1 (en) * | 1991-12-30 | 1993-07-08 | Neurex Corporation | Methods of producing analgesia and enhancing opiate analgesia |
| NZ268969A (en) | 1993-07-23 | 1997-06-24 | Toray Industries | Morphinan derivatives and pharmaceutical compositions |
| WO1995023132A1 (en) * | 1994-02-23 | 1995-08-31 | Cambridge Neuroscience, Inc. | Blockers of ion channels and methods of use thereof |
| AU1888195A (en) * | 1994-03-17 | 1995-10-03 | Nanning Maple Leaf Pharmaceutical Co. Ltd. | The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence |
| GB9513180D0 (en) * | 1995-06-28 | 1995-08-30 | Univ London | Ion channel |
| DE19602970A1 (de) | 1995-12-20 | 1997-07-31 | Nycomed Arzneimittel Gmbh | Neue 7,8- Dihydromorphinderivate, Verfahren zu deren Herstellung und deren Verwendung |
| CN1072486C (zh) * | 1996-09-24 | 2001-10-10 | 王维国 | 用于戒毒、镇痛的药剂及其制法 |
| CN1081034C (zh) * | 1997-03-07 | 2002-03-20 | 潘心富 | 一种双胍基氢化嘌呤环类化合物的戒毒药 |
| WO1998043619A2 (en) * | 1997-04-02 | 1998-10-08 | The Regents Of The University Of California | Method of local anesthesia |
| AU7389098A (en) * | 1997-05-16 | 1998-12-08 | Brigham And Women's Hospital | Local anesthetic formulations |
| DE19936719A1 (de) * | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
| CN1284536C (zh) | 2000-09-18 | 2006-11-15 | 威克斯医药有限公司 | 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用 |
| CN1203857C (zh) * | 2000-09-18 | 2005-06-01 | 威克斯医药有限公司 | 局部麻醉与镇痛的新方法 |
| CN1236773C (zh) * | 2000-11-22 | 2006-01-18 | 南宁枫叶药业有限公司 | 用于镇痛、麻醉或治疗药物依赖性的制剂 |
| CN1269482C (zh) * | 2001-05-18 | 2006-08-16 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
-
2001
- 2001-05-18 CN CNB011180986A patent/CN1269482C/zh not_active Expired - Fee Related
-
2002
- 2002-02-05 US US10/062,483 patent/US6780866B2/en not_active Expired - Fee Related
- 2002-05-20 DE DE60236077T patent/DE60236077D1/de not_active Expired - Lifetime
- 2002-05-20 WO PCT/CN2002/000339 patent/WO2002094272A1/en not_active Ceased
- 2002-05-20 ES ES02734980T patent/ES2344631T3/es not_active Expired - Lifetime
- 2002-05-20 CA CA002485337A patent/CA2485337C/en not_active Expired - Fee Related
- 2002-05-20 EP EP02734980A patent/EP1387685B1/en not_active Expired - Lifetime
- 2002-05-20 AT AT02734980T patent/ATE464903T1/de not_active IP Right Cessation
- 2002-05-20 JP JP2002590989A patent/JP2004529959A/ja active Pending
-
2004
- 2004-05-20 US US10/849,240 patent/US20040214842A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040214842A1 (en) | 2004-10-28 |
| CN1386505A (zh) | 2002-12-25 |
| DE60236077D1 (de) | 2010-06-02 |
| JP2004529959A (ja) | 2004-09-30 |
| EP1387685A1 (en) | 2004-02-11 |
| EP1387685B1 (en) | 2010-04-21 |
| US6780866B2 (en) | 2004-08-24 |
| US20020198226A1 (en) | 2002-12-26 |
| CA2485337C (en) | 2007-08-28 |
| WO2002094272A1 (en) | 2002-11-28 |
| ES2344631T3 (es) | 2010-09-02 |
| CA2485337A1 (en) | 2002-11-28 |
| EP1387685A4 (en) | 2007-05-23 |
| ATE464903T1 (de) | 2010-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mercadante et al. | Opioid-induced tolerance and hyperalgesia | |
| CN1269482C (zh) | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 | |
| CA2407683C (en) | Topical anesthetic/opioid formulations and uses thereof | |
| US6103258A (en) | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics | |
| Duman et al. | Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain | |
| Odunayo et al. | State‐of‐the‐art‐review: immunomodulatory effects of opioids | |
| CN1309562A (zh) | 包括一种阿片样物质镇痛剂和一种nmda拮抗剂的局部给药组合物 | |
| Bhargava et al. | Effect of nitric oxide synthase inhibition on tolerance to the analgesic action of D-Pen2, D-Pen5 enkephalin and morphine in the mouse | |
| Mahesh et al. | Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods | |
| Snoek et al. | Neuropeptide receptors in intestinal disease: physiology and therapeutic potential | |
| Morini et al. | Nociceptin/orphanin FQ prevents ethanol-induced gastric lesions in the rat | |
| CN101039675A (zh) | 河豚毒素及其衍生物用于治疗外周神经源性神经痛 | |
| Fang et al. | Involvement of peripheral beta-endorphin and MU, delta, kappa opioid receptors in electro acupuncture analgesia for prolonged inflammatory pain of rats | |
| CN1907974A (zh) | 具有镇痛作用的石杉碱甲及其衍生物 | |
| CN1486178A (zh) | 组胺受体拮抗剂 | |
| Kim et al. | Therapeutic strategies that target vagal C-fibre terminals for the treatment of chronic cough | |
| CN114642730B (zh) | 一种抑制剂在缓解吗啡耐受中的应用 | |
| Jones et al. | Neurobiology of opioids | |
| Gao et al. | The various functions of opioids in pathophysiological conditions | |
| Shaban et al. | The pharmacological interaction between tramadol and meloxicam on the level of peripheral and visceral analgesia in mice | |
| Opioids | Neurobiology of Opioids | |
| Kotliñska | Are glycine~ B sites involved in the development of morphine tolerance? | |
| Hong et al. | Exploring Nonopioid Analgesic Agents for Intrathecal Use | |
| Krajnik et al. | Topical Opioids—Fact Or Fiction? | |
| CN101151051A (zh) | 钠通道阻断剂及其衍生物与阿片受体拮抗剂的联合制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060816 Termination date: 20120518 |